Effect of glucosamine, a therapeutic agent for osteoarthritis, on osteoblastic cell differentiation

International Journal of Molecular Medicine

Volumn 28, Issue 3, 2011, Pages 373-379

  Igarashi, Mamoru ^a   Sakamoto, Koji ^b   Nagaoka, Isao ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b Koyo Chemical Co Ltd   (Japan)

Author keywords

Glucosamine; Osteoblast; Osteocalcin; Receptor activator of NF B ligand

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN TYPE 1; GLUCOSAMINE; I KAPPA B; N ACETYLGLUCOSAMINE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN;

ANIMAL CELL; ARTICLE; BONE METABOLISM; BONE MINERALIZATION; CELL ACTIVATION; CELL DIFFERENTIATION; CONTROLLED STUDY; MOUSE; NONHUMAN; OSTEOARTHRITIS; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACETYLGLUCOSAMINE; ALKALINE PHOSPHATASE; ANIMALS; CELL DIFFERENTIATION; CELL LINE; COLLAGEN TYPE I; GLUCOSAMINE; GLYCOSAMINOGLYCANS; MICE; OSTEOARTHRITIS; OSTEOBLASTS; OSTEOCALCIN; OSTEOGENESIS; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79959979854     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.686     Document Type: Article

References (49)

1. Gabriel SE, Crowson CS, Campion ME and O'Fallon WM: Direct medical costs unique to people with arthritis. J Rheumatol 24: 719-725, 1997. (Pubitemid 27146091)
2. March LM and Bachmeier CJ: Economics of osteoarthritis: a global perspective. Baillieres Clin Rheumatol 11: 817-834, 1997.
3. Martel-Pelletier J, Lajeunesse D and Pelletier JP: Etiopathogenesis of osteoarthritis. In: Arthritis and Allied Conditions: A Textbook of Rheumatology. Vol 2. 15th edition. Koopman WJ and Moreland LW (eds). Lippincott Williams & Wilkins, Philadelphia, pp2199-2226, 2005.
4. Puhl W, Bernau A, Greiling H, Köpcke W, Pförringer W, Steck KJ Zacher J and Scharf HP: Intra-articular sodium hyaluronate in Osteoarthritis of the knee: a multicenter, double-blind study. Osteoarthritis Cartilage 1: 233-241, 1993.
5. Buckwalter JA and Mankin HJ: Articular cartilage: degeneration and osteoarthritis, repair, regeneration, and transplantation. Instr Course Lect 47: 487-504, 1998.
6. Fenton JI, Chlebek-Brown KA, Peters TL, Caron JP and Orth MW: Glucosamine HCl reduces equine articular cartilage degradation in expiant culture. Osteoarthritis Cartilage 8: 258-265, 2000. (Pubitemid 30620187)
7. Gouze JN, Bordji K, Gulberti S, Terlain B, Netter P, Magdalou J Fournel-Gigleux S and Ouzzine M: Interleukin-1β down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1β-mediated effects in rat chondrocytes. Arthritis Rheum 44: 351-360, 2001.
8. Oegema TR Jr, Deloria LB, Sandy JD and Hart DA: Effect of oral glucosamine on cartilage and meniscus in normal and chymopapain-injected knees of young rabbits. Arthritis Rheum 46: 2495-2503, 2002.
9. Crolle G and D'Este E: Glucosamine sulphate for the management of arthrosis: a controlled clinical investigation. Curr Med Res Opin 7 104-109, 1980. (Pubitemid 11161037)
10. Drovanti A, Bignamini AA and Rovati AL: Therapeutic activity of oral glucosamine sulfate in osteoarthrosis: a placebo-controlled double-blind investigation. Clin Ther 3: 260-272, 1980. (Pubitemid 11122261)
11. Tapadinhas MJ, Rivera IC and Bignamini AA: Oral glucosamine sulphate in the management of arthrosis: report on a multi-centre open investigation in Portugal. Pharmatherapeutica 3: 157-168, 1982. (Pubitemid 13242759)
12. Lopes VA: Double-blind clinical evaluation of the relative efficacy of Ibuprofen and glucosamine sulphate in the management of ostearthrosis of the knee in out-patients. Curr Med Res Opin 8: 145-149, 1982.
13. McAlindon TE, LaValley MP, Gulin JP and Felson DT: Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 283: 1469-1475, 2000. (Pubitemid 30151826)
14. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyene O, Giacovelli G, Henrotin Y, Dacre JE and Gossett C: Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 357: 251-256, 2001. (Pubitemid 32120855)
15. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G and Rovati LC: Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 162: 2113-2123, 2002. (Pubitemid 35168220)
16. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS and Tugwell P: OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 16: 137-162, 2008. (Pubitemid 351222155)
17. Hua J, Sakamoto K, Kikukawa T, Abe C, Kurosawa H and Nagaoka I: Evaluation of the suppressive actions of glucosamine on the interleukin-1β- mediated activation of synoviocytes. Inflamm Res 56: 432-438, 2007. (Pubitemid 350160419)
18. Radin EL and Rose RM: Role of subchondral bone in the initiation and progression of cartilage damage. Clin Orthop Relat Res 213: 34-40, 1986.
19. Bettica P, Cline G, Hart DJ, Meyer J and Spector TD: Evidence for increased bone resorption on patients with progressive knee osteoarthritis. Arthritis Rheum 46: 3178-3184, 2002.
20. Saito Y, Yoshizawa T, Takizawa F, Ikegame M, Ishibashi O, Okuda K, Hara K, Ishibashi K, Obinata M and Kawashima H: A cell line with characteristics of the periodontal ligament fibroblasts is negatively regulated for mineralization and Runx2/Cbfa1/Osf2 activity, part of which can be overcome by bone morphogenetic protein-2. J Cell Sci 115: 4191-4200, 2002. (Pubitemid 35446813)
21. Yoshizawa T, Takizawa F, Iizawa F, Ishibashi O, Kawashima H, Matsuda A, Endo N and Kawashima H: Homeobox protein Msx2 acts as a molecular defense mechanism for preventing ossification in ligament fibroblasts. Mol Cell Biol 24: 3460-3472, 2004. (Pubitemid 38452085)
22. Stanford CM, Jacobson PA, Eanes ED, Lembke LA and Midura RJ: Rapidly forming apatitic mineral in an osteoblastic cell line (UMR 106-01 BSP). J Biol Chem 270: 9420-9428, 1995.
23. Ali MM, Yoshizawa T, Ishibashi O, Matsuda A, Ikegame M, Shimomura J, Mera H, Nakashima K and Kawashima H: PIASxβ is a key regulator of osterix transcriptional activity and matrix mineralization in osteoblasts. J Cell Sci 120: 2565-2573, 2007. (Pubitemid 47323865)
24. Bronckers AL, Gay S, Finkelman RD and Butler WT: Developmental appearance of the Gla proteins (osteocalcin) and alkaline phosphatase in tooth germs and bone of the rat. Bone Miner 2: 361-373, 1987.
25. Rodan GA, Heath JK, Yoon K, Noda M and Rodan SB: Diversity of the osteoblastic phenotype. In: Cell and Molecular Biology of Vertebrate Hard Tissues, Ciba Foundation Symposium 136. Everd D and Harnett S (eds). John Wiley and Sons, Ltd., Chichester, UK, pp78-91, 1988.
26. Weinreb M, Shinar D and Rodan GA: Different pattern of alkaline phosphatase, osteopontin, and osteocalcin expression in developing rat bone visualized by in situ hybridization. J Bone Miner Res 5: 831-842, 1990. (Pubitemid 20294767)
27. Ibaraki K, Termine JD, Whitson SW and Young MF: Bone matrix mRNA expression in differentiating fetal bovine osteoblasts. J Bone Miner Res 7: 743-754, 1992.
28. Stein GS and Lian JB: Molecular mechanisms mediating proliferation/ differentiation interrelationships during progressive development of the osteoblast phenotype. Endocr Rev 14: 424-442, 1993. (Pubitemid 23238925)
29. Malaval L, Modrowski D, Gupta AK and Aubin JE: Cellular expression of bone-related proteins during in vitro osteogenesis in rat bone marrow stromal cell cultures. J Cell Physiol 158: 555-572, 1994. (Pubitemid 24094439)
30. Eriebacher A, Filvaroff EH, Gitelman SE and Derynck R: Toward a molecular understanding of skeletal development. Cell 80: 371-378, 1995.
31. Reddi AH: Bone morphogenesis and modeling: soluble signal sculpt osteosomes in the solid state. Cell 89: 159-161, 1997.
32. Filvaroff E and Derynck R: Bone remodeling: a signaling system for osteoclast regulation. Curr Biol 8: R679-R682, 1998. (Pubitemid 28451022)
33. Lacey DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burgess T, Elliot R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian Y-X, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J and Boyle WJ: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176, 1998. (Pubitemid 28180851)
34. Kobayashi Y, Udagawa N and Takahashi N: Action of RANKL and OPG for osteoclastogenesis. Crit Rev Eukaryot Gene Expr 19: 61-72, 2009.
35. Divine JG, Zazulak BT and Hewett TE: Viscosupplementation for knee osteoarthritis. Clin Orthop Relat Res 455: 113-122, 2006.
36. Yamazaki H, Mano H, Nakatani S and Wada M: The intake of glucosamine increased bone mass by pQCT in ddy mice. Glucosamine Res 3: 1-6, 2007.
37. Matsunaga T, Yanagiguchi K, Yamada S, Ohara N and Ikeda T: Chitosan monomer promotes tissue regeneration on dental pulp wounds. J Biomed Mater Res 76: 711-720, 2006. (Pubitemid 47233479)
38. Kim MM, Mendis E, Rajaoakse N and Kim SK: Glucosamine sulfate promotes osteoblastic differentiation of MG-63 cells via anti-inflammatory effect. Bioorg Med Chem Lett 17: 1938-1942, 2007.
39. Wells L, Whelan SA and Hart WG: O-GlcNAc: a regulatory post-translational modification. Biochem Biophys Res Commun 302: 435-441, 2003. (Pubitemid 36279547)
40. Love DC and Hanover JA: The hexosamine signaling pathway: deciphering the O-GlcNAc code (Review). Sci STKE 312: re13, 2005.
41. Chou TY, Dang CV and Hart GW: Glycosylation of the c-myc transactivation domain. Proc Natl Acad Sci USA 92: 4417-4421, 1995.
42. Han I and Kudlow JE: Reduced O glycosylation of Sp1 is associated with increased proteasome susceptibility. Mol Cell Biol 17: 2550-2558, 1997. (Pubitemid 27175136)
43. Jiang MS and Hart GW: A subpopulation of estrogen receptors are modified by O-linked N-acetylglucosamine. J Biol Chem 272: 2421-2428, 1997.
44. Yang WH, Kim JE, Nam HW, Ju JW, Kim HS Kim YS and Cho JW: Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability. Nat Cell Biol 8: 1074-1083, 2006. (Pubitemid 44473602)
45. Fujiki R, Chikanishi T, Hashiba W, Ito H, Takada I, Roeder RG, Kitagawa H and Kato S: GlcNAcylation of a histone methyltransferase in retinoic-acid-induced granulopoiesis. Nature 459: 455-461, 2009.
46. Kim S-H, Kim Y-H, Song M, An SH, Byun H-Y, Heo K, Lim S, Oh Y-S, Ryu SH and Suh P-G: O-GlcNAc modification modulates the expression of osteocalcin via OSE2 and Runx2. Biochem Biophys Res Commun 362: 325-329, 2007. (Pubitemid 47337089)
47. Ju Y, Hua J, Sakamoto K, Ogawa H and Nagaoka I: Glucosamine, a naturally occurring amino monosaccharide modulates LL-37-induced endothelial cell activation. Int J Mol Med 22: 657-662, 2008.
48. Ju Y, Hua J, Sakamoto K, Ogawa H and Nagaoka I: Modulation of TNF-α-induced endothelial cell activation by glucosamine, a naturally occurring amino monosaccharide. Int J Mol Med 22: 809-815, 2008.
49. Shimizu T, Nakatani S, Kobata K and Wada M: Oral administration of N-acetyl-D-glucosamine and D-glucosamine hydrochloride affects bone mineral density in C57BL/6J mice. Chitin Chitosan Res 17: 74-78, 2011.